SynCardia Systems

Altitude files Preliminary Merger Proxy Statement for Business Combination with Picard

Retrieved on: 
Monday, August 14, 2023
Altitude, ALTU, United States Army Acquisition Corps, SynCardia Systems, Bank statement, Bangladesh Securities and Exchange Commission, PALO, Cryptocurrency

ATLANTA and PALO ALTO, Calif. and TUCSON, Ariz., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Altitude Acquisition Corp. (“Altitude”) (Nasdaq: ALTU) and Picard Medical, Inc. (“Picard”), the parent company of SynCardia Systems, LLC (“SynCardia”), the global leader in mechanical heart replacement technology, today announced the filing of a preliminary proxy statement on Schedule 14A with the U.S. Securities and Exchange Commission (“SEC”), and in connection with their previously announced business combination.

Key Points: 
  • ATLANTA and PALO ALTO, Calif. and TUCSON, Ariz., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Altitude Acquisition Corp. (“Altitude”) (Nasdaq: ALTU) and Picard Medical, Inc. (“Picard”), the parent company of SynCardia Systems, LLC (“SynCardia”), the global leader in mechanical heart replacement technology, today announced the filing of a preliminary proxy statement on Schedule 14A with the U.S. Securities and Exchange Commission (“SEC”), and in connection with their previously announced business combination.
  • Picard also announced the completion of the audit of its financial statements as of and for the year ended December 31, 2022.
  • As previously announced on April 23, 2023, Altitude entered into a definitive business combination agreement with Picard that is expected to result in Picard becoming publicly listed.
  • Completion of the transaction is subject to approval by Altitude’s stockholders and other customary closing conditions.

Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

Retrieved on: 
Wednesday, July 19, 2023
IPO, Cardiovascular disease, Audit committee, Sale, Oslo-Fergene, Patient, Coherent Corp., CFO, National Association, Therapy, SynCardia Systems, Pharmaceutical industry, Akari

NEW YORK and LONDON, July 19, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences executive Wendy DiCicco as interim Chief Financial Officer (CFO).

Key Points: 
  • NEW YORK and LONDON, July 19, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences executive Wendy DiCicco as interim Chief Financial Officer (CFO).
  • Ms. DiCicco has more than 25 years of experience in the life sciences industry, currently serving as an independent financial and board advisor to companies, often in the role of interim CFO.
  • Ms. DiCicco served as CFO for Renovacor, a pre-clinical biopharmaceutical company developing a gene therapy for cardiovascular disease.
  • She also served as interim CFO for FerGene, Inc. a Phase 3 urologic oncology gene therapy company from January 2020 through May 2022.

Picard Medical and its Subsidiary, SynCardia Systems, a Pioneer in Total Artificial Heart Technology, to Become a Publicly Traded Company via Merger with Altitude Acquisition Corp.

Retrieved on: 
Monday, April 24, 2023
Heart, LLP, United States Army Acquisition Corps, Winston & Strawn, Cardiovascular disease, Heart failure, Marketing, TAH, White & Case, Hope, History, Doctor of Philosophy, Death, MDR, Hospital, Acquisition, Patient, Physician, Investment, International Growth Centre, Heart transplantation, ALTU, Growth, FDA, New product development, Medical device, Pharmaceutical industry, Altitude, EU, SynCardia Systems

PALO ALTO, Calif. and TUCSON, Ariz. and ATLANTA, April 24, 2023 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (“Picard Medical”), the parent company of SynCardia Systems, LLC (“SynCardia”), a global leader in mechanical heart replacement technology, today announced that it has entered into a definitive business combination agreement with Altitude Acquisition Corp. (“Altitude”) (NASDAQ: ALTU), a publicly traded special purpose acquisition company, that will result in Picard Medical becoming a publicly listed company.

Key Points: 
  • Upon closing of the transaction, Altitude will be renamed Picard Medical Holdings, Inc. and is expected to remain listed on Nasdaq.
  • SynCardia is working with regulatory authorities to have its CE mark reinstated under EU MDR for most European Union countries.
  • Cardiovascular disease is the leading cause of death globally and has resulted in 64.3 million heart failure patients worldwide.
  • The only definitive therapy for end-stage heart failure is heart transplantation, and it is estimated that 300,000 patients currently require this treatment option.

Bridge to Life Ltd. Names New Chief Financial Officer and Vice-President of Operations

Retrieved on: 
Thursday, January 26, 2023
Eastman Kodak Co v. Harold Worden, Wharton School of the University of Pennsylvania, University, INSEAD, MBA, CFO, IQVIA, Thermo Fisher Scientific, SynCardia Systems, Ecologically based invasive plant management, BD, Fullerton Health Group, The Bridge: The Life and Rise of Barack Obama, Women's health, BS, Management, Economics, Operation

Bob Beechey possesses extensive experience in the life sciences sector, having held senior executive posts at both publicly traded and privately held companies.

Key Points: 
  • Bob Beechey possesses extensive experience in the life sciences sector, having held senior executive posts at both publicly traded and privately held companies.
  • His distinguished track record includes CFO titles at Aspira Women's Health, Quintiles Transnational Corporation, Thermo Fisher Scientific, and Eastman Kodak's Health Group.
  • Blago Herrera brings over three decades of experience in the manufacturing and supply chain operations med tech sector.
  • Adding their experience and expertise to our executive leadership team is the logical next step as Bridge to Life plans to become the global leader in organ preservation."

Bridge to Life Ltd. Announces the Appointment of Bob Beechey as Chief Financial Officer and Blago Herrera as Vice-President of Operations

Retrieved on: 
Wednesday, January 11, 2023
Thermo Fisher Scientific, Ecologically based invasive plant management, Wharton School of the University of Pennsylvania, SynCardia Systems, INSEAD, Women's health, CFO, Herrera, MBA, BS, Growth, The Bridge: The Life and Rise of Barack Obama, IQVIA, University, BD, Eastman Kodak Co v. Harold Worden, Management, Operation, Economics

NORTHBROOK, Ill., Jan. 11, 2023 /PRNewswire/ -- Bridge to Life, Ltd. ("Bridge to Life" or the "Company"), a leading global supplier of organ preservation solutions and organ perfusion technologies, announced the appointment of Bob Beechey as Chief Financial Officer and Blago Herrera as Vice President of Operations.

Key Points: 
  • NORTHBROOK, Ill., Jan. 11, 2023 /PRNewswire/ -- Bridge to Life, Ltd. ("Bridge to Life" or the "Company"), a leading global supplier of organ preservation solutions and organ perfusion technologies, announced the appointment of Bob Beechey as Chief Financial Officer and Blago Herrera as Vice President of Operations.
  • Bob Beechey possesses extensive experience in the life sciences sector, having held senior executive posts at both publicly traded and privately held companies of varying size.
  • His distinguished track record includes CFO titles at Aspira Women's Health, Quintiles Transnational Corporation, Thermo Fisher Scientific, Eastman Kodak's health group, and Arthur Andersen.
  • Beechy earned his MBA from INSEAD and holds a BS in Economics from the esteemed Wharton School of the University of Pennsylvania.

Leonardo DRS Announces Appointment of Eric C. Salzman to Board of Directors

Retrieved on: 
Tuesday, December 6, 2022
Security, Defense, Technology, Other Technology, Networks, Other Defense, ASG, ASG Technologies, Lehman Brothers, Francisco Partners, University, Software, Harvard University, SynCardia Systems, Financial compensation, Communication, Professional Football Compensation Committee, Blackstone, Credit Suisse, M&A, Woman, Leonardo DRS, Multimedia, Growth, Audit committee, Military, Carnegie Learning, The Carlyle Group, MBA, Zenefits, Audit, Management, DRS, ShoreTel

Leonardo DRS, Inc. (DRS) announced today the appointment of Eric C. Salzman to the companys Board of Directors.

Key Points: 
  • Leonardo DRS, Inc. (DRS) announced today the appointment of Eric C. Salzman to the companys Board of Directors.
  • We are delighted to have Eric join our Board of Directors; his deep experience in driving company growth strategies will bring important guidance to DRS as we start our new era as a public company, said Bill Lynn, Chairman and CEO of Leonardo DRS.
  • Mr. Salzman currently serves as the Chief Executive Officer of Safeguard Scientifics, Inc., which he joined in 2020.
  • He has a 25-year track record partnering with public and private growth companies as an investor, board member and strategic advisor.

Bridge to Life Ltd. Names Don Webber as President and CEO

Retrieved on: 
Thursday, October 20, 2022
Lung, State University of New York, Sale, Science, LLC, Air force, NASDAQ, Patient, United, Webber, MBA, Nova Southeastern University, SynCardia Systems, Kidney, The Bridge: The Life and Rise of Barack Obama, Board, CEO, Liver, Safety, State university system, Perfusion, Heart, Industrial technology, Surgeon, Retirement, Management, Life

NORTHBROOK, Ill., Oct. 20, 2022 /PRNewswire/ -- The Board of Directors for Bridge to Life, a world leader in organ preservation, announced Don Webber as the new President and Chief Executive Officer. Webber's appointment comes after Steve Schweighardt, founder, and former CEO for over seventeen years, announced his retirement from daily operations. Schweighardt will remain as Chairman. 

Key Points: 
  • NORTHBROOK, Ill., Oct. 20, 2022 /PRNewswire/ -- The Board of Directors for Bridge to Life, a world leader in organ preservation, announced Don Webber as the new President and Chief Executive Officer.
  • In making the announcement, Schweighardt stated, "We are very pleased to announce that Don will be taking over as President and CEO effective immediately.
  • Webber brings over 30 years of executive leadership experience to Bridge to Life and has extensive experience developing and commercializing medical products.
  • Prior to joining Bridge to Life, Webber served as CEO of SynCardia Systems, LLC, and was responsible for the turnaround and successful sale of the company.

United States Bionics Market Analysis Report 2022-2027 - Lucrative Opportunities in the Usage of Bionic Devices in Defense - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 7, 2022
Biotechnology, Medical Devices, Health, Robotics, Technology, Bionics, Market development, State, Observation, Porter's five forces analysis, Impact, USD, Ansoff Matrix, Investment, Emotion, CAGR, Integrative Production Technology for High-Wage Countries, Competitive analysis, Sonova, Demant, Medtronic, Risk, COVID-19, Growth, Industry, Pharmaceutical industry, Retail, Risk management, Somatosensory system, Technology, SynCardia Systems

The "US Bionics Market (2022-2027) by Product, Technology, Fixation, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Bionics Market (2022-2027) by Product, Technology, Fixation, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The report provides a detailed analysis of the competitors in the market.
  • The report presents a detailed Ansoff matrix analysis for the US Bionics Market.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix.

Face Shields for Medical Staff Now Available from SynCardia Systems, LLC

Retrieved on: 
Thursday, April 9, 2020
Cardiology, Medical specialties, Clothing, SynCardia Systems, Medicine, Artificial heart, Shield, Face shield

Made from the highly transparent and durable thermoplastic PETG, the face shields provide a high degree of protection in a light weight, high visibility form factor.

Key Points: 
  • Made from the highly transparent and durable thermoplastic PETG, the face shields provide a high degree of protection in a light weight, high visibility form factor.
  • The systems lay flat design allows for large quantities of shields to be shipped and stored in a space efficient manner.
  • A limited supply of face shields is available now with additional stock to follow.
  • SynCardia Systems, LLC (Tucson, AZ) is the privately-held manufacturer of the worlds first and only FDA, Health Canada and CE approved temporary Total Artificial Heart.

80% Ethanol Hand Sanitizer Now Available from SynCardia Systems, LLC

Retrieved on: 
Monday, April 6, 2020
Branches of biology, Health, Chemical substances, Hygiene, Cardiology, Disinfectants, Hepatotoxins, Teratogens, SynCardia Systems, Hand sanitizer, Artificial heart, Hand washing

SynCardia is now offering 80% ethanol hand sanitizer for sale in bulk quantities intended for hospitals and other large healthcare organizations as well as food service and federal, state, and local agencies capable of distributing to the areas of greatest need

Key Points: 
  • SynCardia is now offering 80% ethanol hand sanitizer for sale in bulk quantities intended for hospitals and other large healthcare organizations as well as food service and federal, state, and local agencies capable of distributing to the areas of greatest need
    SynCardia Systems, LLC announced today that the company has begun manufacturing and selling an 80% ethanol (alcohol) hand sanitizer.
  • Hand hygiene is an important part of the U.S. response to COVID-19.
  • SynCardia Systems, LLC (Tucson, AZ) is the privately-held manufacturer of the worlds first and only FDA, Health Canada and CE approved temporary Total Artificial Heart.
  • Policy for Temporary Compounding of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency.